Compare Crispr Therapeutics AG (CRSP) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Standard Lithium Ltd — how do they compare? Crispr Therapeutics AG trades at $53.87 (market cap $5.23B), while Standard Lithium Ltd trades at $2.39 (market cap $604.50M). The key difference: Crispr Therapeutics AG is far larger — about 8.7× Standard Lithium Ltd's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| CRSP | SLI | |
|---|---|---|
Market Cap | $5.23B | $604.50M |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $5.65 |
52-Week Low | $44.34 | $1.93 |
Enterprise Value | $3.65B | $467.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
SLI trades at $2.43, down 3.95% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported negative profitability metrics, including a -16.6% ROE and -$48.40M net income for 2025, but has beaten EPS estimates in two recent quarters. Recent news highlights institutional buying and progress on its South West Arkansas lithium project, supported by a $225M DOE grant.
The outlook hinges on successful project execution and lithium production timeline, with analyst consensus strongly bullish (100% buy ratings). Key risks include persistent negative cash flow from operations and high capital expenditure needs, which could pressure the balance sheet if project delays occur.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
